Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 9/20 | 0.36 |
| ▸ | NOS3 | P29474 | 8/20 | 0.36 |
| ▸ | NOS1 | P29475 | 7/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306000 | 0.77 | KDM4E (0.42) | LMNANOS2NOS3NOS1BACE1 | |
| SCHEMBL30000766 | 0.76 | NOS3 (0.41) | NOS2NOS3NOS1KLKB1BACE1 | |
| SCHEMBL7337621 | 0.76 | NOS3 (0.41) | NOS2NOS3NOS1KLKB1BACE1 | |
| SCHEMBL14385061 | 0.76 | NOS3 (0.39) | NOS2NOS3NOS1BACE1DPP4 | |
| SCHEMBL4618573 | 0.76 | KDM4E (0.36) | KLKB1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL7823971 | 0.75 | NOS3 (0.41) | NOS2NOS3NOS1KLKB1BACE1 | |
| Hydrochloric Acid SCHEMBL17442571 | 0.75 | NOS3 (0.41) | NOS2NOS3NOS1KLKB1BACE1 | |
| SCHEMBL17221283 | 0.74 | NOS3 (0.36) | NOS2NOS3NOS1BACE1DPP4 | |
| SCHEMBL4619802 | 0.74 | MAPK1 (0.35) | LMNADPP4 | |
| SCHEMBL4618728 | 0.70 | NPC1 (0.45) | LMNAKLKB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207695-A1 | Thrombin Inhibiting 2-Oxo-1,2,5,6-Tetrahydropyridine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| CN-101243069-A | Thrombin inhibiting 2-oxo-1,2,5,6-tetrahydropyridine derivatives | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1893601-A1 | THROMBIN INHIBITING 2-OXO-1, 2, 5, 6-TETRAHYDROPYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135323-A1 | THROMBIN INHIBITING 2-OXO-1, 2, 5, 6-TETRAHYDROPYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207695-A1 | Thrombin Inhibiting 2-Oxo-1,2,5,6-Tetrahydropyridine Derivatives | F2R, F2, SERPINE1 | LMNA 2604/4885NOS2 453/4885NOS3 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.